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Abstract
Objective
Autoantibodies to melanoma differentiation-associated gene 5 (MDA5) are specifically
expressed in patients with dermatomyositis (DM) and are associated with a subset of DM
patients with rapidly progressive interstitial lung disease (RP-ILD). Here, we examined the
clinical utility of a newly developed enzyme-linked immunosorbent assay (ELISA) system
for detecting these antibodies.
Methods
Here we developed an improved ELISA for detecting anti-MDA5 antibodies. We then per-
formed a multicenter clinical study involving 8 medical centers and enrolled 242 adult
patients with polymyositis (PM)/DM, 190 with non-PM/DM connective tissue disease (CTD),
154 with idiopathic interstitial pneumonia (IIP), and 123 healthy controls. Anti-MDA5 anti-
bodies in the patients’ serum samples were quantified using our newly developed ELISA,
and the results were compared to those obtained using the gold-standard immunoprecipita-
tion (IP) assay. In addition, correlations between the ELISA-quantified anti-MDA5 antibod-
ies and clinical characteristics were evaluated.
Results
In patients with PM/DM, the anti-MDA5 antibody measurements obtained from the ELISA
and IP assay were highly concordant; the ELISA exhibited an analytical sensitivity of
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98.2%, specificity of 100%, positive predictive value of 100%, and negative predictive value
of 99.5% (compared to the IP assay). Anti-MDA5 antibodies were detected in 22.7% of the
DM patients, but not in any of the patients with PM, non-PM/DM CTD, or IIP. Clinically
amyopathic DM, RP-ILD, arthritis, and fever were more prevalent in DM patients who were
anti-MDA5 antibody-positive than in those who were antibody-negative (P 0.0002 for all
comparisons). In addition, anti-MDA5 antibody-positive patients with RP-ILD exhibited
higher antibody levels than those without RP-ILD (P = 0.006).
Conclusion
Our newly developed ELISA can detect anti-MDA5 antibodies as efficiently as the gold stan-
dard IP assay and has the potential to facilitate the routine clinical measurement of anti-
MDA5 antibodies in patients who suspected to have DM.
Introduction
Circulating autoantibodies directed against nuclear or cellular components are commonly
detected in patients with polymyositis (PM) or dermatomyositis (DM) [1]. In addition to well-
characterized PM/DM-specific autoantibodies, such as anti-aminoacyl tRNA synthetase
(ARS), anti-signal recognition particle, and anti-Mi-2 antibodies, a number of additional DM-
specific antibodies have been recently described. These include antibodies against melanoma
differentiation-associated gene 5 (MDA5), transcriptional intermediary factor-1-gamma,
NXP-2, and small ubiquitin-like modifier activating enzyme [2]. The detection of these autoan-
tibodies is highly useful for diagnosing PM/DM. Because of the strong associations of these
autoantibodies with certain clinical characteristics of PM/DM, such as inflammatory myopa-
thy, skin lesions, and interstitial lung disease (ILD), they are important biomarkers for classify-
ing disease subgroups, predicting future organ involvement, and determining the prognosis of
patients with PM/DM [1, 2].
Anti-MDA5 antibodies (also referred to as anti-CADM-140 antibodies) were first identified
in the serum from patients with clinically amyopathic DM (CADM) by immunoprecipitation
(IP) assays and shown to recognize a cytoplasmic 140-kDa protein [3]. The 140-kDa autoanti-
gen was subsequently identified as MDA5, an RNA helicase, by molecular cloning techniques
[4]. The production of anti-MDA5 antibodies is strongly associated with DM, especially with
CADM, and rapidly progressive ILD (RP-ILD), and this subset is associated with particularly
poor clinical outcomes [3–11]. There is currently no evidence-based treatment for RP-ILD in
anti-MDA5 antibody-positive patients; however, intensive immunosuppressive therapy initi-
ated early in the disease, before irreversible lung damage, may improve patient survival [2].
The early detection of anti-MDA5 antibodies helps to identify patients at high risk for develop-
ing life-threating RP-ILD. However, anti-MDA5 antibody measurement is not feasible in rou-
tine clinical laboratories, because the only accurate assay for detecting these antibodies is a
complicated IP assay involving the use of a radioisotope and cultured cells [3]. Previously, two
of us (SS and MK) developed an enzyme-linked immunosorbent assay (ELISA) for detecting
anti-MDA5 antibodies that uses recombinant MDA5 as an antigen source [4]. This assay
exhibits high analytical specificity (100%), but somewhat lower sensitivity (85%) than the gold
standard IP assay. In the present study, we developed an improved version of the ELISA and
examined its clinical utility using a multicenter study involving a large number of PM/DM
patients and disease controls.
Clinical Utility of a New Anti-MDA5 Antibody Assay
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Patients and Methods
Patients and controls
We conducted a multicenter study at 8 medical centers across Japan from October 2011 to
March 2014, and enrolled 242 adult patients with PM/DM, 190 with non-PM/DM connective
tissue disease (CTD), and 154 with idiopathic interstitial pneumonia (IIP). The participants
with PM/DM were consecutive patients at the individual medical centers, while the patients
with non-PM/DM CTD or IIP were randomly selected from the outpatient population. Serum
samples were collected in conjunction with retrospectively collected clinical information. PM/
DM was defined as having definite or probable PM or DM according to the criteria proposed
by Bohan and Peter [12], or having CADM according to the criteria proposed by Sontheimer;
the presence of typical DM rashes for more than 2 years without clinical evidence of muscle
symptoms [13]. The diagnoses of rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), systemic sclerosis (SSc), and primary Sjögren’s syndrome were made according to the
corresponding criteria proposed by the American College of Rheumatology [14–17]. Mixed
connective tissue disease (MCTD) was defined according to published diagnostic criteria [18].
IIP was defined as ILD of unknown cause, including drug or occupational-environmental
exposure, without fulfilling the classification criteria for any specific CTD or vasculitis [19].
Serum samples were collected from all of the patients and from 123 healthy control volunteers
and stored at -20°C until use. Written informed consent was obtained from all of the study par-
ticipants, in accordance with the Declaration of Helsinki. This study was approved by the Insti-
tutional Review Board of Tokai University, Kanazawa University, Kyoto University, Nagasaki
University, Hamamatsu University, Gifu University, and Keio University.
Clinical features
Demographic information, including sex and age at disease onset, was obtained from all
patients. The clinical and laboratory findings of the PM/DM patients were retrospectively col-
lected from medical records. The data obtained included PM/DM subgroup classification (PM,
classic DM, and CADM) and the presence or absence of the following clinical features: helio-
trope rash, Gottron’s sign, arthritis, fever, ILD, and malignancy. ILD was classified as RP-ILD
or chronic ILD based on its progression during the disease course. Patients who exhibited a
radiologic worsening of their ILD with progressive dyspnea and/or hypoxemia within 3
months of respiratory symptom onset were defined as having RP-ILD [4].
IP assay
Serum samples from the study participants were subjected to IP assays using unlabeled or 35S-
labeled HeLa cell extracts to analyze the RNA and protein components of autoantigens, respec-
tively [3]. The sera were defined as anti-MDA5 antibody-positive when they reacted with a
140-kDa protein that was identical to that immunoprecipitated by the anti-MDA5 antibody-
positive reference serum [3]. Anti-Jo-1, anti-EJ, anti-OJ, anti-PL-7, anti-PL-12, and anti-KS
antibodies were identified by precipitation of the corresponding transfer RNA using RNA-IP
assays.
Preparation of recombinant human MDA5 antigen
A full-length complementary DNA encoding human MDA5 was kindly provided by Dr. Taka-
shi Fujita (Kyoto University, Japan) [20]. Recombinant MDA5 protein was expressed as an N-
terminal glutathione S-transferase (GST) fusion protein using a baculovirus expression system
(BaculoGold™, BD Biosciences, San Jose, CA). Insect cells (High Five™; Thermo Fisher
Clinical Utility of a New Anti-MDA5 Antibody Assay
PLOS ONE | DOI:10.1371/journal.pone.0154285 April 26, 2016 3 / 12
Scientific, Waltham, MA, USA) were infected with baculovirus harboring MDA5 and incu-
bated for 72 hours at 27°C. The cells were lysed, and the soluble recombinant MDA5 was puri-
fied on a glutathione Sepharose 4B column (GE Healthcare, Buckinghamshire, UK) and eluted
with 50 mM Tris-HCl (pH 8.0) containing 15 mM glutathione and 1.5 mM dithiothreitol
(DTT). The purity of the recombinant MDA5 was examined by sodium dodecyl sulfate-12.5%
polyacrylamide gel electrophoresis, followed by staining with 0.05% Coomassie blue and densi-
tometric analysis with an Experia™ system (Bio-Rad Laboratories, Hercules, CA). The antige-
nicity of the recombinant MDA5 was analyzed on immunoblots probed with a rabbit anti-GST
polyclonal antibody (Medical and Biological Laboratories, Nagoya, Japan), rabbit anti-MDA5
monoclonal antibody (Cell Signaling Technology, Danvers, MA), or anti-MDA5 antibody-pos-
itive or negative serum samples [4]. After incubating the membrane with peroxidase-conju-
gated anti-rabbit or anti-human IgG (Medical and Biological Laboratories), the
immunoreactive bands were visualized using 3, 3’-diaminobenzidine tetrahydrochloride and
hydrogen peroxide.
Anti-MDA5 antibody ELISA
The anti-MDA5 antibody ELISA was developed primarily by applying a platform used for
measuring anti-ARS antibodies (MESACUP anti-ARS test; Medical and Biological Laborato-
ries) [21]. Briefly, purified recombinant MDA5 diluted to 4 μg/mL in phosphate-buffered
saline (PBS) containing 2 mM DTT was coated onto 96-well Microtiter plates (Maxisorp;
Nunc, Rochester, NY, USA) overnight at 4°C. The plates were washed twice with PBS and
blocked with PBS containing 1% bovine serum albumin (BSA) and 5% sucrose overnight at
4°C. The serum samples were diluted 1:100 in PBS containing 0.5% sodium chloride, 0.15%
Tween 20, 0.2% BSA, 1% casein enzymatic hydrolysate, and 0.2 mg/mL Escherichia coli extract,
and incubated in the blocked plates for 30 minutes at room temperature. The plates were then
washed four times with PBS containing 0.05% Tween 20 and incubated with peroxidase-conju-
gated anti-human IgG (Medical and Biological Laboratories) diluted 1:4,000 in 20 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 135 mM sodium chloride, 1% BSA, and
0.1% p-hydroxyphenylacetic acid. After incubation for 30 minutes at room temperature, the
plates were washed 4 times with PBS containing 0.05% Tween 20, and the bound antibodies
were detected with the peroxidase substrate, 3, 3’, 5, 5’-tetramethylbenzidine. After incubation
for 15 minutes at room temperature, the reaction was stopped by the addition of 0.5 N sulfuric
acid. Absorbance at 450 nm (A450) was measured, and unit values (U/mL) were calculated
from the following formula: 100 × (sample A450—blank A450) / (anti-MDA5-positive reference
A450—blank A450).
Detection of anti-ARS antibodies
Anti-ARS antibodies were detected using a commercial ELISA kit (Medical and Biological Lab-
oratories). This system detects anti-Jo-1, anti-PL-7, anti-EJ, anti-PL-12, and anti-KS antibod-
ies, but does not detect anti-OJ antibody [21]. The presence of individual anti-ARS antibodies
was further confirmed by RNA-IP assays.
Statistical analysis
The cut-off value that best discriminated two groups was determined by receiver operating
characteristic (ROC) curve analysis. All continuous values are shown as the mean ± standard
deviation. Unpaired comparisons of continuous variables were performed using the Mann-
Whitney U test. Categorical variables were compared using a chi-square test or Fisher’s exact
test when appropriate. Pairwise comparison was performed when the 2×3 table chi-square
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results were statistically significant. Statistical analysis was performed using StatView version
5.0 software (Artech, Osaka, Japan).
Results
Clinical characteristics of the enrolled patients
The 242 patients with PM/DM consisted of 70 with PM, 104 with classic DM, and 68 with
CADM. CADM accounted for 40% of the consecutive cohort of total DM patients. This is con-
sistent with the proportion of CADM in independent DM cohorts previously reported in
Japan, ranging form 36% to 43% [3, 5, 22, 23]. The age at disease onset was 55.5 ± 15.1 years,
and 169 patients (70%) were women. ILD was found in 134 of the PM/DM patients (57%), of
which 65 (27%) had RP-ILD and 69 (29%) had chronic ILD. Malignancy was reported in 51 of
the patients (21%). The patients with non-PM/DM CTD included 67 with SLE, 45 with RA, 43
with SSc, 20 with MCTD, 8 with primary Sjögren’s syndrome, 4 with overlapping syndrome,
and 3 with miscellaneous diseases, such as inclusion body myositis, polymyalgia rheumatica,
and anti-neutrophil cytoplasmic antibody-associated vasculitis. The patients with IIP consisted
of 18 (12%) with RP-ILD and 136 (88%) with chronic ILD.
Establishment of an anti-MDA5 antibody ELISA
A recombinant GST-MDA5 fusion protein was expressed and purified using a baculovirus
expression system. The purity of the isolated protein was determined by Coomassie blue stain-
ing followed by densitometry, and shown to be>95% (Fig 1A). To assess the antigenicity of
the GST-MDA5 protein, it was subjected to immunoblot analysis using 6 DM serum samples,
3 of which were anti-MDA5 antibody-positive and 3 of which were anti-MDA5 antibody-nega-
tive, as determined by IP assay (Fig 1B). As expected, the GST-MDA5 protein was specifically
recognized by anti-MDA5 antibody-positive sera as well as by anti-GST and commercial anti-
MDA5 antibodies. Faint ladder bands potentially corresponding to degradation products of
the fusion protein were visible with antibodies that recognized MDA5, but not with the anti-
GST antibody, suggesting that degradation primarily occurred in the GST portion of the fusion
protein, and should not influence antigenicity.
Fig 1. Purity and antigenicity of recombinant GST-MDA5 protein. A. Purified recombinant GST-MDA5
fusion protein (2 μg) was subjected to sodium dodecyl sulfate-12.5% polyacrylamide gel electrophoresis,
followed by 0.05% Coomassie blue staining. The GST-MDA5 fusion protein was detected as a single band at
~166 kDa (arrow).B. Immunoblot analysis of the recombinant fusion protein was performed by probing with
anti-MDA5 antibody-positive DM sera (lanes 1–3), anti-MDA5 antibody-negative DM sera (lanes 4–6), an
anti-GST polyclonal antibody (lane 7), and an anti-MDA5monoclonal antibody (lane 8).
doi:10.1371/journal.pone.0154285.g001
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We next developed an ELISA for detecting anti-MDA5 antibodies using the purified
GST-MDA5 fusion protein as an antigen source. We evaluated the efficiency of the ELISA by
using it to analyze the 242 PM/DM sera. In addition, all of the PM/DM sera were analyzed by
the gold standard anti-MDA5 antibody IP assay. The IP assay showed that 56 of the serum
samples (23.1%) reacted with a 140-kDa protein corresponding to MDA5. In close agreement,
the anti-MDA5 antibody ELISA indicated that 55 of the samples (22.7%) were anti-MDA5
antibody-positive (Table 1). An ROC analysis was conducted to determine the optimal cut-off
level of the ELISA-quantified anti-MDA5 antibody that differentiated between the anti-MDA5
antibody-positive and negative sera, as determined by the IP assay (Fig 2A). This analysis con-
firmed that the ELISA and IP assay results were highly concordant (area under the
curve> 0.99, P< 0.0001). As shown in Fig 2B, an anti-MDA5 antibody level> 32 U/mL was
determined to be the optimal cut-off for predicting positive results in the anti-MDA5 antibody
IP assay, with an analytical sensitivity of 98.2%, specificity of 100%, positive predictive value of
100%, and negative predictive value of 99.5%. The analysis of only one serum resulted in a
false-negative result in the ELISA. This serum was obtained from a patient who had received
immunosuppressive treatment before blood collection, which may have caused the level of
anti-MDA5 antibodies to fall to a level that was undetectable by the ELISA. Nevertheless, these
results indicated that our newly developed anti-MDA5 antibody ELISA is a sensitive and spe-
cific method that has the potential to replace the gold standard IP assay.
Table 1. Frequencies of anti-MDA5 and anti-ARS antibodies detected by ELISA.
Diagnosis Number of samples Anti-MDA5 antibody Anti-ARS antibody* P
PM/DM, overall 242 55 (22.7%) 54 (22.3%) 1.0
PM 70 0 21 (30.0%) < 0.0001
Classic DM 104 10 (9.6%) 30 (28.8%) 0.0008
CADM 68 45 (66.2%) 3 (4.4%) < 0.0001
Non-PM/DM CTD 190 0 5 (2.6%) 0.07
IIP 154 0 14 (9.1%) 0.0003
Healthy controls 123 0 0 1.0
*This assay is able to detect anti-Jo-1, anti-EJ, anti-PL-7, anti-PL-12, and anti-KS antibodies, but does not detect anti-OJ antibody.
doi:10.1371/journal.pone.0154285.t001
Fig 2. ROC curve analysis to determine the optimal cut-off value for ELISA-quantified anti-MDA5
antibodies. A. The ROC curve showed high concordance between the ELISA and IP assay (area under the
curve > 0.99, P < 0.0001). B. The sensitivity and specificity of the anti-MDA5 antibody ELISA for various
cutoff levels. A cutoff of 32 U/mL (arrow) provided a sensitivity of 98.2% and specificity of 100%.
doi:10.1371/journal.pone.0154285.g002
Clinical Utility of a New Anti-MDA5 Antibody Assay
PLOS ONE | DOI:10.1371/journal.pone.0154285 April 26, 2016 6 / 12
Screening of anti-MDA5 and anti-ARS antibodies in the study
participants
Next, we analyzed the anti-MDA5 antibody levels in the serum samples from 190 patients with
non-PM/DM CTD, 154 patients with IIP, and 123 healthy controls using the anti-MDA5 anti-
body ELISA (Fig 3A). Notably, anti-MDA5 antibodies were not detected in any of these sam-
ples, including those from 18 patients with RP-ILD in the IIP group (Table 1). Interestingly, of
the 55 (22.7%) PM/DM patients who were anti-MDA5 antibody-positive, only those patients
diagnosed with either classic DM or CADM, but not PM, were anti-MDA5 antibody-positive.
The clinical sensitivity and specificity for the diagnosis of DM, including classic DM and
CADM, was 32.0% and 100%, respectively. Moreover, the positive and negative predictive val-
ues were 100% and 99.5%, respectively.
We also quantified the anti-ARS antibody levels in the serum samples of all of the study par-
ticipants (Fig 3B). Anti-ARS antibodies were detected in patients with PM/DM, and in small
numbers of patients with non-PM/DM CTD or IIP (Table 1), including 3 with SSc, and one
each with SLE and MCTD. The overall clinical sensitivity and specificity of the anti-ARS
ELISA for PM/DM was 22.3% and 94.5%, respectively. The prevalence of anti-MDA5 and anti-
ARS antibodies in patients with PM/DM was almost identical, but their distribution across the
PM/DM subgroups was quite different. While the anti-MDA5 antibodies were preferentially
detected in patients with CADM, the anti-ARS antibodies were predominantly found in
patients with PM or classic DM. Although we detected both types of antibodies in 2 patients
with classic DM by ELISA analysis, it is likely that the anti-ARS antibody ELISA results in
these cases were false positives, since the corresponding IP assays failed to confirm the presence
of anti-ARS antibodies in these sera. Thus, our findings suggested that the presence of anti-
MDA5 and anti-ARS antibodies was mutually exclusive in our study participants. The com-
bined clinical sensitivity of the 2 antibodies was 44.2% in overall PM/DM patients; 30.0% in
PM patients, 36.5% in classic DM patients, and 70.6% in CADM patients.
Fig 3. Anti-MDA5 (A) and anti-ARS (B) antibody levels in patients with PM/DM, non-PM/DM CTD, IIP,
and healthy controls. Anti-MDA5 and anti-ARS antibodies were measured by ELISA in the sera from 242
patients with PM/DM (70 PM, 104 classic DM, and 68 CADM), 190 patients with non-PM/DM CTD, 154
patients with IIP, and 123 healthy volunteers. Cutoff levels of anti-MDA5 and anti-ARS antibodies are shown
as broken lines (32 and 25 U/mL, respectively).
doi:10.1371/journal.pone.0154285.g003
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Clinical features associated with anti-MDA5 antibodies detected by
ELISA in patients with DM
Since anti-MDA5 antibodies were detected exclusively in patients with DM, we examined the
clinical features associated anti-MDA5 antibody positivity in 172 patients with DM, including
the classic DM and CADM patients. We divided the DM patients into 3 groups: patients who
were anti-MDA5 antibody-positive, patients who were anti-ARS antibody-positive, and
patients who were negative for both antibodies (antibody-negative patients). We then com-
pared the demographic and clinical findings among the 3 groups (Table 2). We found that the
age at initial examination was lower in patients with anti-MDA5 antibodies and tended to be
lower in those with anti-ARS antibodies, compared with that of antibody-negative patients
(P = 0.005 and P = 0.06, respectively). Classic DM was less frequent and CADM was more fre-
quent in anti-MDA5 antibody-positive patients than in anti-ARS-positive or antibody-negative
patients (P< 0.0001 for both comparisons). The overall frequency of ILD was similar between
the anti-MDA5-positive and anti-ARS-positive groups, and was significantly greater than that
of the antibody-negative group (P< 0.0001 for both comparisons). RP-ILD was more common
in the anti-MDA5-positive group, while chronic ILD was more frequent in the anti-ARS-posi-
tive group, compared with the other 2 groups (P< 0.0001 for all comparisons). Therefore,
anti-MDA5 antibody detection was useful for predicting RP-ILD development in patients with
DM, with a sensitivity of 84%, specificity of 86%, positive predictive value of 73%, and negative
predictive value of 92%. We also found that the anti-MDA5 antibody levels were significantly
higher in anti-MDA5 antibody-positive DM patients with RP-ILD than in those without
RP-ILD (231.0 ± 55.6 versus 168.6 ± 79.7, P = 0.006).
Heliotrope rash was more prevalent in the anti-MDA5-positive than in the anti-ARS-positive
group (P = 0.02), while arthritis was more common in the anti-MDA5-positive group than in the
antibody-negative group (P< 0.0001). Fever was more commonly found in anti-MDA5-positive
patients than in anti-ARS-positive or antibody-negative patients (P = 0.01 and P = 0.0002,
Table 2. Clinical characteristics of patients with DM, stratified by autoantibody status.
Demographic and clinical ﬁndings Anti-MDA5 positive* Anti-ARS positive* Anti-MDA5/anti-ARS negative P†
(n = 55) (n = 31) (n = 86)
Age at onset, mean ± SD 50.8 ± 14.3 52.9 ± 15.7 58.4 ± 17.3 0.01
Female, % 72.7 83.9 66.3 0.17
DM subgroup
Classic DM, % 18.2 90.3 76.7 < 0.0001
CADM, % 81.8 9.7 23.3 < 0.0001
ILD overall, % 90.9 80.6 27.9 < 0.0001
ILD type
RP-ILD, % 83.6 25.8 10.5 < 0.0001
Chronic ILD, % 7.3 54.8 17.4 < 0.0001
Gottron’s sign, % 87.3 67.7 79.1 0.10
Heliotrope rash, % 49.1 25.8 55.8 0.02
Arthritis, % 65.5 48.4 22.1 < 0.0001
Fever, % 61.8 35.5 30.2 0.0008
Malignancy, % 5.5 9.7 34.9 < 0.0001
*Two patients who were positive for both anti-MDA5 and anti-ARS by ELISA, but were negative for anti-ARS by IP assay were included in the anti-
MDA5-positive group.
†Statistical analysis was performed by chi-square tests on a 2 × 3 table.
doi:10.1371/journal.pone.0154285.t002
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respectively). Finally, malignancy was less frequent in anti-MDA5 or anti-ARS antibody-positive
patients than in antibody-negative patients (P< 0.0001 and P = 0.007, respectively).
When clinical characteristics were compared between DM patients with and without anti-
MDA5 antibodies, 55 patients positive for anti-MDA5 antibodies represented younger disease
onset (P = 0.01); higher frequency of CADM (P< 0.0001), ILD (P< 0.0001), RP-ILD
(P< 0.0001), arthritis (P< 0.0001), and fever (P = 0.0002); and lower frequency of classic DM
(P< 0.0001), chronic ILD (P = 0.002), and malignancy (P = 0.0005), compared with 117 nega-
tive for anti-MDA5 antibodies.
The majority of anti-MDA5 antibody-positive DM patients were classified as having CADM,
although there were 10 patients positive for anti-MDA5 antibodies had classic DM. To further
examine if associated clinical features in patients with CADM and classic DMwere different,
clinical characteristics were compared between classic DM patients with anti-MDA5 and anti-
ARS antibodies (Table 3). Even within patients with classic DM, anti-MDA5 antibody was asso-
ciated with RP-ILD and fever, while anti-ARS antibody was associated with chronic ILD.
Discussion
In this study, we verified the efficiency of a newly developed anti-MDA5 antibody ELISA in a
multi-center study involving patients with various connective tissue diseases or those with IIP.
The new ELISA uses highly purified recombinant MDA5 protein as the antigen source and a
platform that was previously validated in the commercial anti-ARS antibody detection kit; these
features represent improvements over the original ELISA [4]. As a result, the new system
achieved an analytical sensitivity and specificity that were comparable to those of the gold stan-
dard IP assay. Therefore, the new anti-MDA5 antibody ELISA has the potential to replace the IP
assay, which is a complicated and time-consuming procedure that is currently performed only in
some research laboratories. Since the ELISA can be used to screen large numbers of sera quickly
and efficiently, it would be suitable for detection of anti-MDA5 antibodies in clinical practice.
Using the new ELISA, we showed that anti-MDA5 antibodies were highly specific to
patients with DM, in particular to patients with CADM, and was not detected in patients with
PM. Notably, we did not detect these antibodies in any of the non-PM/DM CTD or IIP
patients. The strong association of anti-MDA5 antibody positivity with DM is consistent with
previous reports [3, 4, 7–11]. In contrast, anti-ARS antibodies were detected in patients with
Table 3. Comparisons of clinical characteristics in classic DM patients with anti-MDA5 and anti-ARS antibodies.
Demographic and clinical ﬁndings Anti-MDA5 positive* Anti-ARS positive* P
(n = 10) (n = 28)
Age at onset, mean ± SD 55.4 ± 14.8 54.3 ± 15.8 0.83
Female, % 60.0 82.1 0.21
ILD overall, % 80.0 85.7 0.64
ILD type
RP-ILD, % 70.0 25.0 0.02
Chronic ILD, % 10.0 53.6 0.02
Gottron’s sign, % 90.0 67.9 0.24
Heliotrope rash, % 60.0 28.6 0.13
Arthritis, % 60.0 50.0 0.72
Fever, % 80.0 35.7 0.03
Malignancy, % 10.0 10.7 1.00
*Two patients who were positive for both anti-MDA5 and anti-ARS by ELISA, but were negative for anti-ARS by IP assay were included in the anti-
MDA5-positive group.
doi:10.1371/journal.pone.0154285.t003
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various CTDs and even in patients with IIP, but were more prevalent in patients with PM/DM.
Because of the mutually exclusive expression of anti-MDA5 and anti-ARS antibodies, the
simultaneous measurement of both autoantibodies is predicted to improve the clinical diagno-
sis of PM/DM. In this regard, both anti-MDA5 and anti-ARS antibodies produce cytoplasmic
staining by indirect immunofluorescence in routine autoantibody screening.
The majority of anti-MDA5 antibody-positive patients in this study lacked clinical findings
indicative of inflammatory myopathy, and were diagnosed with CADM. This finding is consis-
tent with those of previously published studies [3–8, 10], including a meta-analysis that dem-
onstrated strong associations of anti-MDA5 antibodies with CADM in Japanese adult patients,
and with classic DM in North American, Chinese, and Korean patients [10]. In the same study,
the sensitivity and specificity of anti-MDA5 antibody detection for identifying RP-ILD in PM/
DM patients were shown to be 77% and 86%, respectively. Our anti-MDA5 ELISA showed a
similar level of performance in diagnosing RP-ILD in DM patients, suggesting that this assay
system should be useful for detecting RP-ILD in the early phases of the disease and in making
treatment decisions. Since the anti-MDA5 antibodies were never detected in IIP patients who
did not exhibit DMmanifestations, even though 18 of them had been diagnosed with RP-ILD,
the production of these antibodies appears to be tightly associated with RP-ILD in the context
of DM, but not with RP-ILD alone.
Anti-MDA5 antibodies detected by our new ELISA were associated with arthritis, fever, and
lack of malignancy, in addition to CADM and RP-ILD. These clinical associations were princi-
pally consistent with previous studies [3, 6, 7, 24–27]. In addition, it has been reported that
ulcerations and palmer papules are characteristic skin manifestations in patients with anti-
MDA5 antibodies [7, 8, 25], but these clinical features was not recorded in our cohort. This is
one of limitations of this study.
One of the advantages of the ELISA over the IP assay is that it provides quantitative results.
We previously conducted a longitudinal analysis of anti-MDA5 antibody levels in DM patients
using the previous version of the ELISA [28, 29], and found that high levels of anti-MDA5 anti-
bodies at diagnosis were useful for predicting poor outcomes. In addition, we reported that the
reduction and subsequent disappearance of antibodies during the course of immunosuppres-
sive treatment was associated with favorable outcomes. The present study, involving a larger
number of patients, confirmed the correlation between high antibody levels and RP-ILD.
Taken together, these findings suggest that the anti-MDA5 antibody ELISA will be useful not
only for early diagnosis and timely prediction of RP-ILD development, but also for monitoring
disease activity and evaluating therapeutic efficacy.
In summary, we have shown that our newly developed anti-MDA5 antibody ELISA exhib-
ited efficacy that was equivalent to that of the gold standard IP assay. The incorporation of this
assay into routine clinical testing has the potential to improve the outcomes of patients with
DM and RP-ILD by facilitating early diagnosis, timely intervention, and proper monitoring of
disease activity.
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